These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 31290076

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, BSc AB, Martel C, Vaillancourt M, Balser J, Moyneur É, members of the VVA Prasterone Research Group.
    Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É, VVA Prasterone Research Group.
    Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
    [Abstract] [Full Text] [Related]

  • 5. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy.
    Archer DF, Labrie F, Montesino M, Martel C.
    J Steroid Biochem Mol Biol; 2017 Nov; 174():1-8. PubMed ID: 28323042
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review.
    Portman DJ, Goldstein SR, Kagan R.
    Climacteric; 2019 Feb; 22(1):65-72. PubMed ID: 30554531
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.
    Labrie F, Derogatis L, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É, Members of the VVA Prasterone Research Group.
    J Sex Med; 2015 Dec; 12(12):2401-12. PubMed ID: 26597311
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens.
    Labrie F, Martel C, Bérubé R, Côté I, Labrie C, Cusan L, Gomez JL.
    J Steroid Biochem Mol Biol; 2013 Nov; 138():359-67. PubMed ID: 23954500
    [Abstract] [Full Text] [Related]

  • 13. Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner.
    Labrie F, Montesino M, Archer DF, Lavoie L, Beauregard A, Côté I, Martel C, Vaillancourt M, Balser J, Moyneur E, other participating Members of the Prasterone Clinical Research Group.
    Climacteric; 2015 Nov; 18(6):817-25. PubMed ID: 26517756
    [Abstract] [Full Text] [Related]

  • 14. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.
    Martel C, Labrie F, Archer DF, Ke Y, Gonthier R, Simard JN, Lavoie L, Vaillancourt M, Montesino M, Balser J, Moyneur É, other participating members of the Prasterone Clinical Research Group.
    J Steroid Biochem Mol Biol; 2016 May; 159():142-53. PubMed ID: 26972555
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intravaginal 6.5 mg prasterone administration in postmenopausal women with overactive bladder syndrome: A pilot study.
    Matarazzo MG, Sarpietro G, Fiorito D, Di Pasqua S, Ingrassano S, Panella MM, Cianci A, Caruso S.
    Eur J Obstet Gynecol Reprod Biol; 2021 Aug; 263():67-71. PubMed ID: 34167036
    [Abstract] [Full Text] [Related]

  • 17. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
    Archer DF, Kimble TD, Lin FDY, Battucci S, Sniukiene V, Liu JH.
    J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator.
    Montesino M, Labrie F, Archer DF, Zerhouni J, Côté I, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Moyneur E, Balser J.
    Gynecol Endocrinol; 2016 Mar; 32(3):240-5. PubMed ID: 26634942
    [Abstract] [Full Text] [Related]

  • 19. The vagina as source and target of androgens: implications for treatment of GSM/VVA, including DHEA.
    Cipriani S, Maseroli E, Ravelli SA, Vignozzi L.
    Climacteric; 2023 Aug; 26(4):309-315. PubMed ID: 37288964
    [Abstract] [Full Text] [Related]

  • 20. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J.
    Menopause; 2009 Aug; 16(5):923-31. PubMed ID: 19424093
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.